![]() |
市場調查報告書
商品編碼
1679225
栓劑包裝市場預測至 2030 年:按包裝類型、材料、應用和地區進行的全球分析Suppository Packaging Market Forecasts to 2030 - Global Analysis By Packaging Type (Blister Packaging, Strip Packaging and Form-Fill-Seal (FFS) Packaging), Material, Application and By Geography |
根據 Stratistics MRC 的數據,2024 年全球栓劑包裝市場價值為 4.2304 億美元,預計到 2030 年將達到 6.602 億美元,預測期內的複合年成長率為 7.7%。
為保護、儲存和管理栓劑而設計的專門包裝選項稱為栓劑包裝。這些包裝可防止污染,同時確保產品的完整性、衛生規範和管理的便利性。為了維持產品有效性,栓劑包裝必須提供防潮、防光和防溫度變化的阻隔保護。它作為陰道和直腸栓劑廣泛應用於製藥和醫療領域。
醫療支出增加
全球醫療保健支出的增加是栓劑包裝市場發展的主要驅動力。隨著政府和個人向醫療保健分配更多的資源,對包括栓劑在內的藥品的投資正在增加。這些資金承諾促進了先進藥物輸送系統的開發和採用,從而產生了對高品質包裝解決方案的需求。人口老化,特別是已開發地區的人口老化,正在加速這一趨勢,因為老年人口需要更多的藥物。
嚴格的監管核准
FDA 等監管機構對藥品包裝制定了嚴格的標準,以確保產品的安全性、穩定性和有效性。這些法規要求進行大量的測試、記錄和合規程序,從而延長了產品開發時間並增加了製造商的成本。此外,由於不同地區的法規不盡相同,迫使企業調整其包裝解決方案以符合不同市場的不同標準。這些挑戰尤其影響中小型製造商,他們努力獲得在複雜的監管環境中生存所需的資金和技術資源。
包裝材料創新
生物分解性和環保材料的開發響應了日益成長的環境問題,並與製藥業的永續性一致。結合物聯網功能的智慧包裝技術能夠在儲存和運輸過程中實現狀況監控,提高產品安全性和患者依從性。先進材料具有更好的阻隔性能,可抵禦濕氣、光線和溫度變化,從而延長產品的保存期限並保持功效。此外,易於管理的材料可以提高患者的舒適度。這些創新有可能透過更有效率的製造流程和減少材料廢棄物來節省成本。
認知和接受度有限
儘管該療法具有治療作用,但由於文化禁忌以及患者對直腸和陰道給藥方式的不適,許多地區拒絕採用該療法。醫療保健提供者可能還會猶豫是否開立栓劑,因為他們認為患者不喜歡它們,這限制了市場滲透。此外,缺乏關於正確的給藥技術和栓劑與口服藥物相比的益處的教育也阻礙了市場的成長。這項挑戰在保守社會和新興市場尤其明顯,因為這些社會更傾向於採用替代管理方法。
COVID-19 疫情最初透過供應鏈挑戰和製造限制擾亂了栓劑包裝市場。然而,這場危機隨後加速了某些市場趨勢,例如人們更加關注藥品包裝的完整性和無菌性。疫情提高了人們對藥品安全性和穩定性的認知,推動了對高品質包裝解決方案的需求。此外,醫療產業在疫情期間迅速適應新挑戰,刺激了藥品包裝的創新,包括增加保護功能的栓劑包裝設計和可安全在家中使用的易於使用的給藥方法。
預計預測期內鋁/聚乙烯 (Alu/PE) 部分將成為最大的部分。
預計鋁/聚乙烯 (Alu/PE) 材料將在預測期內佔據最大的市場佔有率,因為它兼具優異的阻隔性和功能性。這種包裝材料提供了卓越的防潮、防光、防氧和防污染保護,確保了栓劑在使用前的穩定性和有效性。這種材料的化學惰性可防止與封裝藥物發生相互作用,其物理耐用性可在處理和運輸過程中保護精密栓劑,因此受到全球製藥商的青睞。
預計預測期內尿道部分將以最高的複合年成長率成長。
由於泌尿系統疾病盛行率的不斷上升和靶向藥物輸送系統的進步,預計尿道部分將在預測期內呈現最高的成長率。對於需要局部治療的情況,尿道栓劑可以提供直接有效的藥物給藥,與口服藥物相比,全身副作用較少。藥物傳遞技術的發展提高了尿道栓劑的有效性和舒適度,從而被醫療保健專業人士擴大採用。此外,人口老化和泌尿器官系統疾病發病率高也進一步推動了對這些專門治療方案的需求。
預計預測期內歐洲地區將佔據最大的市場佔有率。這是因為與其他地區相比,這裡的製藥業更加成熟,醫療保健基礎設施更加先進,並且對栓劑劑型的文化接受度更高。歐洲國家長期以來一直使用栓劑作為處方藥和非處方藥,因此對高品質的包裝解決方案有著穩定的需求。該地區對藥品包裝的嚴格監管標準也推動了採用優質包裝材料,以確保產品的穩定性和安全性。此外,歐洲人口老化和醫療支出的增加進一步促進了歐洲栓劑包裝市場的持續成長。
在預測期內,由於醫療保健基礎設施的擴大、製藥製造活動的增加以及印度和中國等國家的醫療保健支出的增加,預計亞太地區將呈現最高的複合年成長率。該地區不斷成長的人口和不斷改善的醫療服務創造了巨大的市場機會。此外,人們對先進藥物傳遞系統的認知不斷提高,以及醫療環境中對栓劑劑型的逐漸接受,進一步推動了全部區域市場的成長。
According to Stratistics MRC, the Global Suppository Packaging Market is accounted for $423.04 million in 2024 and is expected to reach $660.20 million by 2030 growing at a CAGR of 7.7% during the forecast period. Specialized packaging options made to safeguard, store, and administer suppository drugs are referred to as suppository packaging. These packaging's guard against contamination while guaranteeing product integrity, hygienic practices, and convenience of administration. To preserve product efficacy, suppository packaging needs to offer barrier protection against moisture, light, and temperature changes. It is extensively utilized for vaginal and rectal suppositories in the pharmaceutical and medical sectors.
Rising healthcare expenditure
The increasing healthcare expenditure globally is a significant driver for the suppository packaging market. As governments and individuals allocate more resources to healthcare, there is greater investment in pharmaceutical products, including suppositories. This financial commitment enables the development and adoption of advanced drug delivery systems, creating demand for high-quality packaging solutions. The aging population, particularly in developed regions, further accelerates this trend as older demographics require more medications.
Stringent regulatory approvals
Regulatory bodies like the FDA impose rigorous standards for pharmaceutical packaging to ensure product safety, stability, and efficacy. These regulations necessitate extensive testing, documentation, and compliance procedures, which extend product development timelines and increase costs for manufacturers. Additionally, regulations vary across regions, requiring companies to adapt their packaging solutions to meet different standards in various markets. These challenges particularly affect smaller manufacturers who may struggle with the financial and technical resources needed to navigate complex regulatory landscapes.
Innovations in packaging materials
The development of biodegradable and eco-friendly materials addresses growing environmental concerns and aligns with sustainability initiatives in the pharmaceutical industry. Smart packaging technologies incorporating IoT features enable condition monitoring during storage and transit, enhancing product safety and patient compliance. Advanced materials with improved barrier properties against moisture, light, and temperature fluctuations extend product shelf life and maintain efficacy. Additionally, materials that facilitate administration improve patient experience. These innovations potentially reduce costs through more efficient manufacturing processes and reduced material waste.
Limited awareness and acceptance
Despite their therapeutic advantages, cultural taboos and patient discomfort regarding rectal or vaginal administration methods create resistance to adoption in many regions. Healthcare providers may also hesitate to prescribe suppositories due to perceived patient reluctance, limiting market penetration. Additionally, the lack of education about proper administration techniques and benefits of suppositories compared to oral medications further constrains market growth. This challenge is particularly pronounced in conservative societies and emerging markets where alternative delivery methods are preferred.
The COVID-19 pandemic initially disrupted the suppository packaging market through supply chain challenges and manufacturing restrictions. However, the crisis subsequently accelerated certain market trends, including increased focus on pharmaceutical packaging integrity and sterility. The pandemic heightened awareness about medication safety and stability, driving demand for high-quality packaging solutions. Additionally, the healthcare industry's rapid adaptation to new challenges during the pandemic fostered innovation in pharmaceutical packaging, including suppository packaging designs with enhanced protective features and user-friendly administration methods that could be used safely at home.
The aluminum/PE (Alu/PE) segment is expected to be the largest during the forecast period
The aluminum/PE (Alu/PE) segment is expected to account for the largest market share during the forecast period due to its superior combination of barrier properties and functionality. This packaging material provides excellent protection against moisture, light, oxygen, and contaminants, ensuring the stability and efficacy of suppository formulations until use. The material's chemical inertness prevents interaction with the enclosed medication, while its physical durability protects delicate suppositories during handling and transportation, making it the preferred choice for pharmaceutical manufacturers worldwide.
The urethral segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the urethral segment is predicted to witness the highest growth rate due to the increasing prevalence of urological conditions and advancements in targeted drug delivery systems. Urethral suppositories provide direct and efficient medication administration for conditions requiring localized treatment, reducing systemic side effects compared to oral medications. Developments in drug delivery technologies have improved the efficacy and comfort of urethral suppositories, driving their adoption among healthcare professionals. Additionally, the growing aging population, who experience higher rates of urological issues, further fuels demand for these specialized treatment options.
During the forecast period, the Europe region is expected to hold the largest market share owing to a well-established pharmaceutical industry, advanced healthcare infrastructure, and greater cultural acceptance of suppository dosage forms compared to other regions. European countries have long-standing traditions of suppository use in both prescription and over-the-counter medications, creating a stable demand for high-quality packaging solutions. The region's stringent regulatory standards for pharmaceutical packaging also drive the adoption of premium packaging materials that ensure product stability and safety. Additionally, Europe's aging population and increasing healthcare expenditure further contribute to the sustained growth of the suppository packaging market across the continent.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by expanding healthcare infrastructure, increasing pharmaceutical manufacturing activities, and rising healthcare expenditure across countries like India and China. The region's large and growing population, coupled with improving access to healthcare services, creates substantial market opportunities. Additionally, increasing awareness about advanced drug delivery systems and the gradual acceptance of suppository dosage forms in medical practice are further accelerating market growth throughout the region.
Key players in the market
Some of the key players in Suppository Packaging Market include NextPharma Technologies, CordenPharma, Recipharm AB, Valmatic S.R.L., Sarong S.p.A., Key International, HySum Europe GmbH, FAMAR Health Care Services, Hudi Pharma HQ, Adragos Pharma, LGM Pharma, Aluberg s.p.a., Delpharm, Unither, Trefoil Packaging Pvt Ltd and Gerresheimer AG.
In October 2022, CordenPharma Launches Oral Solid Dose GMP Manufacturing for Clinical Trial Development. Because Oral Solid Dose (OSD) capabilities are in high demand, CordenPharma made the strategic decision to enhance our offering with an investment of €10 million into the design and installation of a new GMP Clinical Trial Development (CTD) facility located in CordenPharma Plankstadt (DE). The installment of the new CTD facility is a response to our customers' demands and the recognition of gaps in scale and technologies.
In October 2022, Swedish multinational CDMO Recipharm has bolstered its sterile filling capabilities at its facility in Kaysersberg, France, by installing Lab+ continuous automated technology. The low-volume blow-fill-seal (BFS) process has a throughput speed of 2,000 doses per hour and can be easily adapted for a range of different product types and dosage designs, Recipharm said.